Lipoic Acid Supplement for Cystine Stone
Açar sözlər
Mücərrəd
Təsvir
Cystinuria is a rare inherited autosomal recessive disorder of the kidney that is the result of a defect in the dibasic amino acid transporter in the renal proximal tubule and small intestine. Supersaturation of cystine in the urine produces crystals that precipitate and form calculi, which can be a cause of obstruction, infection, and chronic kidney disease (Chillarón 2010).
One potential therapeutic is a thiol-containing compound alpha-lipoic acid (thioctic acid, 5-(1,2-dithiolan-3- yl) pentanoic acid, ALA). It is an over-the-counter supplement with antioxidant property. Once ALA is transported into the cell, it is reduced to dihydrolipoic acid (DHLA). Both ALA and DHLA have direct antioxidant activity (Scholich 1989), and they can regenerate endogenous antioxidants including ascorbic acid and vitamin E. It can also increase intracellular coenzyme Q10 and glutathione levels. ALA and DHLA also have additional biochemical effects as metal chelators, reactive oxygen species scavengers, and modulators of signaling transduction of several pathways (Gomes 2014).
While the potential therapeutic effects of ALA have been studied in a number of diseases including, for example, Alzheimer's disease, obesity, cardiovascular disease, hypertension, and several cancers (Gomes 2014), the efficacy of ALA has been best studied in type 2 diabetic peripheral neuropathy (Ziegler 2011). In our lab, results from a mouse model of cystinuria show that ALA markedly slows the initiation of cystine stone formation as well as the growth of existing stones.
Given this history in clinical medicine and, most importantly, based upon our positive findings of ALA effectiveness in a mouse model of cystinuria, we propose a pilot study on the use of this molecule in cystinuric patients.
Tarixlər
Son Doğrulandı: | 06/30/2020 |
İlk təqdim: | 09/19/2016 |
Təxmini qeydiyyat təqdim edildi: | 09/19/2016 |
İlk Göndərmə: | 09/21/2016 |
Son Yeniləmə Göndərildi: | 07/22/2020 |
Son Yeniləmə Göndərildi: | 07/26/2020 |
Həqiqi Təhsilin Başlama Tarixi: | 06/18/2017 |
Təxmini İlkin Tamamlanma Tarixi: | 11/30/2022 |
Təxmini İşin Tamamlanma Tarixi: | 11/30/2023 |
Vəziyyət və ya xəstəlik
Müdaxilə / müalicə
Dietary Supplement: ALA supplement
Drug: Placebo
Faza
Qol Qrupları
Qol | Müdaxilə / müalicə |
---|---|
Experimental: ALA supplement Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.
Subjects in this study arm will be taking one supplement tablet containing 1200 mg of alpha lipoic acid orally once daily for three years.
At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size. | Dietary Supplement: ALA supplement Already mentioned in arm/group descriptions. |
Placebo Comparator: Placebo Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.
Subjects in this study arm will be taking one placebo tablet containing 10 mg of sucrose orally once daily for three years.
At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size. | Drug: Placebo Already mentioned in arm/group descriptions. |
Uyğunluq Kriteriyaları
Təhsil üçün uyğun yaşlar | 18 Years Üçün 18 Years |
Təhsilə Uyğun Cinslər | All |
Sağlam Könüllüləri qəbul edir | Bəli |
Kriteriyalar | Inclusion Criteria: - Documented cystinuria on prior 24-hour urine collection and/or stone analysis; history of previous cystine kidney stones. - Being able and willing to provide consent. Exclusion Criteria: - Poorly controlled diabetes mellitus (hemoglobin A1C > 8.0% for more than 1 year). - Current alpha-lipoic acid administration at the time of screening or within the last year prior to screening. - Vulnerable populations including incarceration status. - Unable to give informed consent. - Non-English primary language. - Pregnancy, lactation, or child-bearing age without birth control devices. - Anticipation of pregnancy during the study period. - Serious illness likely to cause death within the next 5 years. |
Nəticə
İlkin nəticə tədbirləri
1. Cystine stone recurrence [3 years]
İkincili Nəticə Tədbirləri
1. Urinary cystine level [3 years]